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Macroautophagy (afterward named autophagy) is a central 
process participating in coordinating energy metabolism, 
recycling of damaged organelles, and in degrading protein 
aggregates and pathogens. One of the important regulators 
of autophagy is the AMP-activated protein kinase (AMPK), 
a heterotrimeric complex with a catalytic PRKAA/α subunit 
and regulatory PRKAB/β and PRKAG/γ subunits. AMPK is 
a key sensor of the cellular energy status recognizing increas-
ing ADP/AMP levels through its PRKAG/γ subunit in cells. 
Activation also requires phosphorylation of the PRKAA/α 
subunit at threonine 172 (T172) by STK11/LKB1 (serine/ 
threonine kinase 11). Downstream effectors are components 
of the ULK1/Atg1 complex and the PIK3C3/VPS34- 
containing class III phosphatidylinositol 3-kinase 
(PtdIns3 K) complex, both of which are necessary for the 
induction of autophagy. Substrates of AMPK are ULK1 and 
two PtdIns3 K complex components, BECN1 (beclin 1) and 
PIK3C3/VPS34. These findings suggest that both complexes 
are directly controlled by the energy sensor AMPK. However, 
the precise mechanisms that are triggered by the AMPK- 
dependent phosphorylation are not well understood. 
Moreover, it is unclear whether the substrates noted above 
are the only downstream effectors of AMPK. With this infor-
mation in mind, the question we wanted to address is whether 
additional substrates exist that connect AMPK to the induc-
tion of autophagy. In this effort we identified CCNY (cyclin 
Y)-CDK16 as a downstream, positive effector of AMPK- 
induced autophagy.
We first applied recombinant AMPK to a protein micro-
array in the presence of 33P-γ-ATP [1]. This approach has 
advantages and disadvantages compared to other methods 
that are used to define substrates. Advantages include the 
fact that direct phosphorylation reactions can be observed. 
The proteins on the array, more than 9000, were expressed in 
insect cells using a baculovirus system. Thus, the proteins 
carry at least some post-translational modifications that 
might be relevant for being recognized by AMPK or any 
other kinase analyzed in such an experimental system. 
Moreover, the proteins are spotted in comparable concentra-
tions, which might help to define low-abundance substrates. 
But of course it is an in vitro experiment, which is a major 
limitation. Of note is that these arrays are no longer manu-
factured, most likely a response to the ever more powerful 
mass spectrometry approaches that allow the analysis of entire 
phospho-proteomes of a cell.
Our in vitro and cellular analyses supported the mass 
spectrometry data that implicated serine 326 (S326) as the 
phospho-acceptor site on CCNY by AMPK. CCNY associates 
with different cyclin-dependent kinases (CDKs), including 
CDK14, CDK15, and CDK16. These different kinase com-
plexes have been poorly studied. Unlike the situation for 
other CDKs, none of the three kinases seems to have 
a major impact on the cell cycle. Rather, they are associated 
with cellular differentiation and with intracellular transport 
processes. Because of the strong link between AMPK and 
autophagy, the three CCNY-CDK complexes were tested for 
effects on autophagy. Importantly, only CCNY in complex 
with CDK16, but neither with CDK14 nor CDK15, affects 
autophagy. The more detailed analysis revealed that overex-
pression of CCNY-CDK16 stimulates autophagy dependent 
on the presence of ULK1 and BECN1, suggesting that CCNY- 
CDK16 regulates autophagy upstream of the ULK1 and 
PtdIns3 K complexes (Figure 1). In contrast, reducing or 
eliminating the expression of CCNY-CDK16 interferes with 
AMPK-induced autophagy, indicating that AMPK is indeed 
upstream of CCNY-CDK16. Mechanistically the S326 phos-
phorylation by AMPK promotes the interaction of CCNY 
with CDK16, which in turn autophosphorylates S336, which 
serves as a marker for active CCNY-CDK16.
What needs to be addressed now? The key question is to 
identify the substrates of CCNY-CDK16 that mediate its sti-
mulatory role on autophagy. Little is known about substrates 
of this kinase and even less about its specificity. Thus, efforts 
have to be developed to determine mechanistic links between 
CCNY-CDK16 and substrates relevant for regulation and/or 
execution of autophagy. One might assume that components 
of the ULK1 and PtdIns3 K complexes are substrates; how-
ever, the dependence of CCNY-CDK16-induced autophagy 
on ULK1 and BECN1 might simply suggest that some essen-
tial process is no longer functional and that CCNY-CDK16 is 
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not sufficient to overcome the defect. Thus, critical substrates 
may exist in either of the two complexes, but further down-
stream targets are also possible.
Can one make predictions where in the autophagy process 
a CCNY-CDK16 substrate might be located? As discussed in our 
paper, CDK16 functions in vesicular transport and in actin cytos-
keleton organization, both being relevant for autophagy. Thus, 
CCNY-CDK16 might have substrates that are involved in 
providing membrane components for the initial phagophore for-
mation or that are important late in autophagy, for example, by 
bringing autophagosomes in close proximity to lysosomes. In this 
context the interaction between SEC23 of the COPII complex and 
CDK16 has to be mentioned. Besides directly regulating the induc-
tion of autophagy, CCNY-CDK16 could also be involved in balan-
cing the cellular decisions between autophagy and apoptosis. 
Pointing to this function is the cyclin-dependent kinase inhibitor 
Figure 1. Model of the interaction of AMPK with CCNY-CDK16 and downstream implications for the induction of autophagy. Under low energy status, AMPK induces 
autophagy by negatively regulating the MTOR complex, and thus reducing protein biosynthesis, and activating the ULK1/Atg1 and PIK3C3/VPS34-containing 
PtdIns3 K complexes that promote phagophore formation and cargo loading. Additionally, AMPK has to phosphorylate CCNY at S326 to activate the CCNY-CDK16 
complex for the induction of autophagy. The phosphorylation of CCNY at S326 allows the interaction with CDK16 and promotes the kinase activity of the complex. 
This in turn stimulates auto-phosphorylation of CCNY at S336, a modification that indicates an active kinase complex. We suggest CCNY-CK16 phosphorylates factors 
associated with the autophagic machinery (red arrows). These factors might function early in the process, for example, as part of the ULK1/Atg1 and PIK3C3/VPS34 
PtdIns3 K complexes, or further downstream, as indicated by the question marks.
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CDKN1B/p27KIP1, which promotes autophagy and inhibits apop-
tosis, and has been described as a CCNY-CDK16 substrate. We 
expect that screening for substrates and their functional character-
ization will provide answers to these questions.
Finally, the association of autophagy with disease, including 
inflammatory, tumorigenic and neurodegenerative processes, is 
worth pointing out. If CCNY-CDK16 is an important regulator 
of these diseases, alterations in the function of this kinase might be 
expected. Indeed, links to inflammatory bowel disease for CCNY 
and to cancer for CDK16 have been established. Moreover, the 
high expression in neuronal cells, with a functional and direct 
interaction with CDK5, suggests a link of CCNY-CDK16 to neu-
rodegeneration. However, little direct evidence supports the sug-
gestion that CCNY-CDK16 kinase activity is involved in these 
processes at present. Again, defining CCNY-CDK16 substrates 
may provide links toward one or the other disease that can be 
addressed experimentally. Thus, CCNY-CDK16 may emerge as 
a drug target.
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